INTRODUCTION {#s1}
============

Cancer is a worldwidely major problem affecting public health \[[@R1]\]. In 2016, 1,685, 210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States \[[@R2]\]. In China, cancer incidence and mortality have been increasing, making cancer the leading cause of death since 2010 \[[@R3]\]. Much of the rising burden of disease is attributable to the occurrence of cancers.

Many tumors express the miR-148/152 family differently in the process of tumorigenesis. MicroRNA (miRNA) is a class of evolutionarily conserved, single-stranded, non-coding RNA molecule (containing about 22 nucleotides) \[[@R4]\], it is estimated to regulate 30 % of all genes in animals by binding to specific sites in the 30 untranslated regions (30UTR), resulting in RNA silencing or post-transcriptional regulation of gene expression \[[@R5]\].

MiRNA-148 (MiR-148) and miR-152 are members of the miR-148/152 family, which consists of miR-148a, miR-148b and miR-152 \[[@R6]\]. The pre-miR-148/152 family have a stem-loop structure, which can be processed into the mature miR-148/152 family by a set of intracytoplasmic enzymes and intranuclear \[[@R7]\]. Mature miR-148/152 family is 21--22 nucleotides in length, with the same seed sequence of about 6--7 nucleotides, which is an important region for binding to target mRNAs \[[@R8]\]. Researches have found that mature miR-148/152 family can involve in different tumor biological processes through complementary binding between the seed sequence and the 30UTR of target mRNAs \[[@R9]\]. Therefore, miR-148/152 family might be critical for these processes.

Due to the diverse and crucial roles of miRNAs in tumors, clarifying the prognostic significance and exploring the complex function in various human cancer tissues about tumorigenesis and/or tumor suppression of the miR-148/152 family may provide constructive insights to efficacious cancers management.

In the present study, a systematic review with the data available from studies published in this field was carried out. We mainly focus on the expression level of miR-148a/b which can be used as prognostic classifiers to guide therapeutic decisions.

MATERIALS AND METHODS {#s2}
=====================

Data sources and search strategy {#s2_1}
--------------------------------

Ethics committee is not applicable in this study {#s2_2}
------------------------------------------------

The present study is conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines \[[@R10]\] and the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) issued by Stroup et al. \[[@R11]\].

We conducted a computerized literature search on multiple databases including PubMed, EMBASE and Web of Science through March 2017. The search items were combinations of "microRNA-148a" or "miR-148a", "microRNA-148b" or "miR-148b", "microRNA-152" or "miR-152" and "neoplasms" or "cancer". We also searched the Google Scholar, Chinese National Knowledge Infrastructure (CNKI) and Wanfang database following the same keywords as assistance. We also manually searched original studies on this topic to further identify potentially relevant articles that may have been missed by the computerized search.

Study selection and exclusion criteria {#s2_3}
--------------------------------------

Eligible studies will be included in the present study if they were: (i) cohort studies assessing the prognostic significance of miR-148/152 family detected in patients with cancer; (ii) reported survival outcome or provided suffcient data to extrapolate the corresponding outcome measures (hazard ratios, HRs and 95% confidence intervals, 95% CIs); (iii) measured in cancer tissue or serum; and (iv) available in English or Chinese.

The exclusion criteria included: (i) reviews, non-human research, comments letters or laboratory studies; (ii) non- Chinese or English articles; (iii) redundant publications using the same population; and (iv) lacked key information regarding survival outcomes, such as HRs or 95%CIs or unable to calculate such parameters. If a study had overlapping data with other studies, we kept the study with larger sample size.

The retrieved articles were assessed for inclusion by FJD and YJF independently and discrepancies were resolved via discussion or consensus.

Data extraction {#s2_4}
---------------

Two independent reviewers (FJD and ZXY) identified eligibility studies using this search strategy to generate a list of potentially relevant articles, and to carry on data extraction and quality evaluation. Discrepancies were resolved by consensus.

The following characteristics and numbers were collected from each eligible study if they were available: first author, publication year, country of origin, histological classification, TNM stage, sample type and size, detection method, follow-up and value of cutoff, HRs of miR-148/152 family for overall survival (OS) and/or progressive free survival (PFS), recurrence free survival (RFS), disease free survival (DFS) and the corresponding 95% CIs, all these results were considered as independent data sets.

If data not reporting, the HR and 95% CI were extrapolated using the methods of Parmar \[[@R12]\] and Tierney \[[@R13]\].

Quality assessment {#s2_5}
------------------

Quality assessment criteria were utilized to evaluate methodological quality of included studies based on Newcastle-Ottawa Scale (NOS) \[[@R14]\]. The instrument rates observational studies on a nine-point scale, and the maximum score was nine, a high-quality study was defined as one with a score of ≥ 6. Discrepancies were resolved through consensus.

The specific Quality In Prognosis Studies (QUIPS) was evaluated according to the approach of Hayden et al. \[[@R15]\]. The estimated items with potential bias included study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, statistical analysis and reporting. The assessments were processed independently by two authors (XLF and KJW) and the final decision was achieved by consensus or consultation of a third party.

Data synthesis and statistical analysis {#s2_6}
---------------------------------------

We utilized RevMan 5.3.5 software (Version 5.3.5 for Windows, Cochrane Collaboration, Oxford, UK) and STATA software version 13.1MP (StataCorp, College Station, TX, USA) to perform this meta-analysis. HRs and corresponding 95% CIs were used to estimate the relationship strength between miR-148/152 family expression and patients' prognosis. Cochran\'s Q test and Higgin\'s *I*^2^ statistic was utilized to measure between-study heterogeneity. If heterogeneity did exist (Pheterogeneity \< 0.05 or *I*^2^ \> 50%), random-effects model (DerSimonian and Laird method) \[[@R16]\] was used to calculate pooled HR, and meta-regression were further applied to investigate sources of heterogeneity \[[@R17]\]. If not, fixed-effects model (Mantel-Haenszel method) \[[@R18]\] was applied. The stratified assessments were conducted by ethnicity (Caucasian, Asian) and cancer subtypes, if one cancer type included no more than two individual studies, it was combined into the 'other cancers' group.

To assess the influence of selected studies on the pooled results, one-way sensitivity analyses were performed, and then by omitting each study in turn to assess the quality and consistency of the results.

Publication bias was evaluated using Begg\'s test (rank correlation test) \[[@R19]\] and Egger\'s test (weighted linear regression test) \[[@R20]\]. An asymmetric funnel plot would suggest the possibility of small studies not being published due to unfavorable results.

The significance of pooled HR was determined by the *Z*-test, *P* \< 0.05 was considered statistically significant, all *P* values were two-sided.

RESULTS {#s3}
=======

Literature search and study characteristics {#s3_1}
-------------------------------------------

The search process and the final selection of relevant studies are shown in Figure [1](#F1){ref-type="fig"} and a total of 1253 studies were identified by cautious searching and screening strategies. After excluding of duplicated studies, the remaining articles were 234. According to the exclusion criteria, 174 articles were further removed based on title or abstract screening. After further identification the individual study. According to the inclusion criteria, 25 articles \[[@R21]--[@R45]\] underwent full-text assessment, and two articles \[[@R21], [@R22]\]were excluded due to data duplication \[[@R26], [@R28]\]. Finally, a total of 23 articles \[[@R23]--[@R45]\] (26 studies), including 12 for miR-148a \[[@R23]--[@R34]\], 8 for miR-148b \[[@R26], [@R35]--[@R41]\] and 6 for miR-152 \[[@R26], [@R40], [@R42]--[@R45]\] respectively were included in evidence synthesis.

![Flow chart of literature search and study selection](oncotarget-08-77999-g001){#F1}

The baseline characteristics of eligible studies were summarized in Table [1](#T1){ref-type="table"}. These eligible studies were published from 2010 to 2016 and included a total of 2641 patients from China, Korea, Norway, Spain, Denmark, America, Iran, France and Tohoku. The patients were classified Asian or Caucasian according to their ethnic background. The types of carcinomas in these studies included ovarian cancer, osteosarcoma, gastric cancer (GC), colorectal cancer, hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC), endometrial serous adenocarcinoma (ESC) and pancreatic cancer. The detection method of miR-148/152 family were quantitative real-time polymerase chain reaction (qRT-PCR) in 26studies, and the remaining one study was Microarray. MiR-148/152 family expression levels were measured in tissue or Serum. The cutoff values of miR-148/152 family vary between the different studies, most with normal or median.

###### Clinicopathological characteristics of eligible studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                   Year   Country   Ethnicity   Locus           Number   Histology   TNM\                Sample   Assay            Follow-up\   Cut-off   Hazard ratios   
                                                                                             Stage                                         (Months)                               
  ------------------------ ------ --------- ----------- --------------- -------- ----------- ------------------- -------- ---------------- ------------ --------- --------------- -------
  Gong \[[@R23]\]          2016   China     Asian       148a            102                  Ovarian cancer      I-IV     Serum            qRT-PCR      60        Normal          HR/SC

  Zhang \[[@R24]\]         2016   China     Asian       148a            92                   Osteosarcoma        I-III    Frozen tissue    qRT-PCR      43        Median          SC

  Qiu \[[@R25]\]           2016   China     Asian       148a            238                  Gastric cancer      I-IV     Frozen tissue    qRT-PCR      84        Median          HR/SC

  Wang F \[[@R26]\]        2016   China     Asian       148a,148b,152   76                   HCC                 I-IV     Serum            qRT-PCR      36        Median          HR/SC

  Ma \[[@R27]\]            2016   China     Asian       148a            126                  Bladder Cancer      I-III    Frozen tissue    qRT-PCR      120       Median          HR/SC

  Ma \[[@R28]\]            2014   China     Asian       148a            89       PFS,89      Osteosarcoma        NA       Serum            qRT-PCR      97        Normal          HR/SC

  Heo\[[@R29]\]            2014   Korea     Asian       148a            59       RFS,59      HCC                 I-IV     Frozen tissue    qRT-PCR      76        Normal          SC

  Kjersem \[[@R30]\]       2014   Norway    Caucasian   148a            150      PFS,150     Colorectal cancer   NA       Serum            qRT-PCR      60        Median          HR

  Li \[[@R31]\]            2014   China     Asian       148a            75                   ESCC                I-III    Frozen tissue    qRT-PCR      47        Median          SC

  Takahashi \[[@R32]\]     2012   Spain     Caucasian   148a            201      DFS,200     Colorectal cancer   I-IV     Frozen tissue    qRT-PCR      144       Median          HR/SC

  Schultz \[[@R33]\]       2012   Denmark   Caucasian   148a            256                  Pancreatic Cancer   NA       Frozen tissue    qRT-PCR      196       Median          HR/SC

  Huang \[[@R34]\]         2012   China     Asian       148a                     RFS,40      Multiple myeloma    I-III    Frozen tissue    Microarray   52        Normal          SC

  Wang RF \[[@R35]\]       2016   China     Asian       148b            65                   NSCLC               I-IV     Frozen tissue    qRT-PCR      60        Median          HR/SC

  Benson \[[@R36]\]        2015   America   Caucasian   148b                     PFS,17      Ovarian Cancer      NA       Serum            qRT-PCR      25        Median          SC

  Ziari \[[@R37]\]         2015   Iran      Caucasian   148b            101                  HCC                 I-IV     Frozen tissue    qRT-PCR      92        Normal          HR/SC

  Ge \[[@R38]\]            2015   China     Asian       148b            151                  NSCLC               I-IV     Frozen tissue    qRT-PCR      60        Normal          HR/SC

  Zhang \[[@R39]\]         2015   China     Asian       148b            40                   HCC                 I-III    Frozen tissue    qRT-PCR      48        Normal          SC

  Jiang \[[@R40]\]         2015   China     Asian       148b,152                 RFS,252     Bladder cancer      NA       Serum            qRT-PCR      48        Normal          HR/SC

  Zhang \[[@R41]\]         2014   China     Asian       148b            156                  HCC                 I-IV     Frozen tissue    qRT-PCR      60        Median          HR/SC

  Wang Y \[[@R42]\]        2016   China     Asian       152             202                  Colorectal cancer   I-IV     Frozen tissue    qRT-PCR      48        Median          HR/SC

  Wang NG \[[@R43]\]       2015   China     Asian       152             80                   Osteosarcoma        I-III    Frozen/ Tissue   qRT-PCR      60        Normal          HR/SC

  Sanfiorenzo \[[@R44]\]   2013   France    Caucasian   152                      DFS,52      NSCLC               I-III    Frozen tissue    qRT-PCR      66        Median          HR/SC

  Hiroki \[[@R45]\]        2010   Tohoku    Asian       152             21       DFS,21      ESC                 I-IV     Frozen tissue    qRT-PCR      72        Median          HR/SC
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer; ESC, endometrial serous adenocarcinoma; qRT-PCR, quantitative real-time PCR; OS, overall survival; PFS, progressive free survival; DFS, disease free survival; RFS, recurrence free survival; SC, survival curve.

Qualitative assessment {#s3_2}
----------------------

Based on the QUIPS Tool, the Table [2](#T2){ref-type="table"} summarizes the 6 bias domains (participation, attrition, prognostic factor measurement, confounding measurement and account, outcome measurement, and analysis and reporting) and the risk of bias legend in Figure [2](#F2){ref-type="fig"}. According to the NOS ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}), seventy-eight percent (18/23) of these articles were high-quality (quality score ≥ 6).

###### Quality assessment of included studies based on the Quality In Prognosis Studies (QUIPS)

  Study                         Quality evaluation of prognosis study   Total Score^a^   Level of Evidence^b^                                      
  ----------------------------- --------------------------------------- ---------------- ---------------------- -------- -------- -------- ------- --------
  Gong 2016 \[[@R23]\]          Yes                                     Partly           Yes                    Yes      Partly   Yes      **6**   **2b**
  Zhang 2016 \[[@R24]\]         Partly                                  Partly           Partly                 Partly   Partly   Partly   **5**   **2b**
  Qiu 2016 \[[@R25]\]           Partly                                  Partly           Yes                    Yes      Partly   Yes      **6**   **2b**
  Wang F 2016 \[[@R26]\]        Partly                                  Partly           Yes                    Yes      Partly   Yes      **6**   **2b**
  Ma 2016 \[[@R27]\]            Yes                                     Partly           Yes                    Yes      Partly   Yes      **7**   **2b**
  Ma 2014 \[[@R28]\]            Yes                                     Partly           Yes                    Yes      Partly   Yes      **8**   **2b**
  Heo 2014 \[[@R29]\]           Partly                                  Partly           Yes                    Partly   Partly   Partly   **7**   **2b**
  Kjersem 2014 \[[@R30]\]       Yes                                     Partly           Yes                    Yes      Partly   Partly   **7**   **1b**
  Li 2014 \[[@R31]\]            Yes                                     Yes              Yes                    Yes      Partly   Yes      **8**   **2b**
  Takahashi 2012 \[[@R32]\]     Yes                                     Yes              Yes                    Yes      Partly   Yes      **8**   **1b**
  Schultz 2012 \[[@R33]\]       Yes                                     Yes              Partly                 Partly   Partly   Yes      **5**   **2b**
  Huang 2012 \[[@R34]\]         Partly                                  Partly           Partly                 Partly   Partly   Partly   **5**   **2b**
  Wang RF 2016 \[[@R35]\]       Partly                                  Yes              Yes                    Yes      Partly   Yes      **7**   **2b**
  Benson 2015 \[[@R36]\]        Yes                                     Yes              Yes                    Yes      Partly   Yes      **6**   **1b**
  Ziari 2015 \[[@R37]\]         Yes                                     Partly           Partly                 Yes      Partly   Yes      **7**   **2b**
  Ge 2015 \[[@R38]\]            Partly                                  Partly           Yes                    Yes      Partly   Yes      **6**   **2b**
  Zhang 2015 \[[@R39]\]         Partly                                  Partly           Partly                 Yes      Partly   Yes      **4**   **2b**
  Jiang 2015 \[[@R40]\]         Yes                                     Partly           Yes                    Yes      Partly   Yes      **5**   **2b**
  Zhang 2014 \[[@R41]\]         Yes                                     Yes              Yes                    Yes      Partly   Yes      **8**   **2b**
  Wang Y 2016 \[[@R42]\]        Yes                                     Yes              Yes                    Yes      Partly   Partly   **8**   **2b**
  Wang NG 2015 \[[@R43]\]       Yes                                     Partly           Yes                    Yes      Partly   Yes      **7**   **2b**
  Sanfiorenzo 2013 \[[@R44]\]   Yes                                     Partly           Yes                    Partly   Partly   Yes      **6**   **2b**
  Hiroki 2010 \[[@R45]\]        Yes                                     Yes              Yes                    Yes      Partly   Yes      **6**   **1b**

^a^Quality assessment of included studies based on the Newcastle-Ottawa Scale.

^b^The levels of evidence were estimated for all included studies with the Oxford Centre for Evidence Based Medicine criteria.

![Forest plots of studies evaluating the HRs of high and low miR-148b expression with respect to OS](oncotarget-08-77999-g002){#F2}

Overall analyses {#s3_3}
----------------

For the miR-148a, HRs for OS were provided by 11 studies, a significant association was observed between low miR-148a level and poor OS in patients (pooled HR = 1.59, 95% CI: 1.14--2.20, *P* = 0.00) [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. HRs for disease progression (DFS/PRS/RFS) were provided by 5 studies, no significantly correlation between miR-148a and DFS/PRS/RFS has been found (HR = 0.90, 95% Cl: 0.47--1.76, *P* = 0.77) (Table [3](#T3){ref-type="table"}). Subgroup analysis was carried out by ethnicity. The expression of miR-148a was not significantly correlated with OS in Asain (HR = 1.61, 95% Cl: 0.87--2.95, *P* = 0.13) and Caucasian (HR = 1.13, 95% Cl: 0.84--1.51, *P* = 0.43). Similarly, miR-148a expression was not significantly correlated with DFS/PRS/RFS in Asain (HR = 0.71, 95% Cl: 0.15--3.27, *P* = 0.66) and Caucasian (HR = 1.15, 95% Cl: 0.50--2.67, *P* = 0.34) (Table [3](#T3){ref-type="table"}). Furthermore, subgroup analysis was performed according to cancer subtypes, the results showed that a low expression level of miR-148a significantly predicted poor OS in digestive tract cancer (DTC) (HR = 1.29, 95%CI: 1.03--1.63, *P* = 0.03). However, subgroup analysis by cancer subtypes, there was no significant risk association was observed in the DFS/PRS/RFS pooled analysis (Table [3](#T3){ref-type="table"}).

###### Main results of pooled HRs in the meta-analysis

  Comparisons             Heterogeneity test   Summary HR (95% CI)   Hypothesis test   Patients            Studies                 
  ----------------------- -------------------- --------------------- ----------------- ------------------- --------- ------ ------ ----
  ***MircroRNA-148a***                                                                                                             
  ***Total***                                                                                                                      
  OS                      115.47               0.00                  91                1.59 (1.14,2.20)    2.77      0.00   1464   11
  DFS/PRS/RFS             24.78                0.00                  84                0.90 (0.47,1.76)    0.30      0.77   538    5
  ***Ethnicity***                                                                                                                  
  OS                                                                                                                               
  Asian                   88.47                0.00                  91                1.61 (0.87,2.95)    1.52      0.13   857    8
  Caucasian               11.40                0.00                  82                1.13 (0.84,1.51)    0.79      0.43   607    3
  DFS/PRS/RFS                                                                                                                      
  Asian                   13.15                0.00                  85                0.71 (0.15,3.27)    0.45      0.66   188    3
  Caucasian               10.27                0.00                  90                1.15 (0.50,2.67)    0.34      0.74   350    2
  ***Cancer subtypes***                                                                                                            
  OS                                                                                                                               
  DTC                     20.64                0.00                  76                1.29 (1.03,1.63)    2.18      0.03   799    6
  Other cancers           83.57                0.00                  95                1.50 (0.52,4.36)    0.75      0.45   665    5
  DFS/PRS/RFS                                                                                                                      
  DTC                     16.90                0.00                  88                0.61 (0.17,2.22)    0.75      0.45   409    3
  Other cancers           7.19                 0.01                  86                1.51 (0.34,6.71)    0.54      0.59   129    2
  ***MircroRNA-148b***                                                                                                             
  ***Total***                                                                                                                      
  OS                      2.08                 0.84                  0                 2.09 (1.70,2.56)    7.05      0.00   589    6
  DFS/PRS/RFS             1.36                 0.24                  26                1.13 (0.62,2.04)    0.40      0.69   269    2
  ***Cancer subtypes***                                                                                                            
  OS                                                                                                                               
  HCC                     1.51                 0.68                  0                 1.97 (1.52,2.56)    5.10      0.00   373    4
  NSCLC                   0.10                 0.75                  0                 2.29 (1.64,3.18)    4.91      0.00   216    2
  ***MircroRNA-152***                                                                                                              
  ***OS***                13.21                0.00                  77                1.04 (0.26,4.17)    0.06      0.95   379    4
  DFS/RFS                 4.74                 0.09                  58                3.49 (1.13,10.83)   2.17      0.03   325    3

DTC, digestive tract cancer, including colorectal cancer, esophageal squamous cell carcinoma, pancreatic pancer and hepatocellular carcinoma.

For the miR-148b, HRs for OS were provided by 6 studies, a significant association was observed between low miR-148b level and poor OS in patients (pooled HR = 2.09, 95%CI: 1.70--2.56, *P* = 0.00) (Figure [2](#F2){ref-type="fig"}). HRs for disease progression (DFS/PRS/RFS) were provided by 2 studies, which indicated no significantly correlation between miR-148b expression and DFS/PRS/RFS (HR = 1.13, 95%Cl: 0.62--2.04, *P* = 0.69) (Table [3](#T3){ref-type="table"}). Subgroup analysis was performed based on cancer subtypes, miR-148b expression was significantly correlated with OS in patients with HCC (HR = 1.97, 95%Cl: 1.52--2.56, *P* = 0.00) and NSCLC (HR = 2.29, 95%Cl: 1.64--3.18, *P* = 0.00) (Table [3](#T3){ref-type="table"}).

For the miR-152, HRs for OS were provided by 4 studies, miR-152 expression was not significantly correlated with OS in cancer (HR = 1.04, 95%Cl: 0.26--4.17, *P* = 0.95). However, it was significantly correlated with DFS/RFS in cancer (HR = 3.49, 95%Cl: 1.13--10.86, *P* = 0.03). Due to the limited availability of eligible studies, stratified study hasn\'t been conducted (included studies populations were all Asians except one Caucasian) (Table [3](#T3){ref-type="table"}).

Meta-regression analysis {#s3_4}
------------------------

When evaluating the association between the miR-148/152 family expression and the risk of cancer, we found that there were significant heterogeneity among studies of miR-148a and miR-152, but we only evaluated the source of heterogeneity of miR-148a due to limited published data of miR-152. Thus, we conducted a meta-regression analysis to investigate potential source of heterogeneity by publication year, cancer types, ethnicity, languages, assays, sample sizes (100 as the boundary), quality (Based on NOS score). Meta-regression analysis indicated that the systemic outcomes were not affected by above characteristics (Table [4](#T4){ref-type="table"}).

###### Publication bias of miR-148a and mir-148b for Begg\'s test and Egger\'s test

  Comparisons            Begg\'s test   Egger\'s test                   
  ---------------------- -------------- --------------- ------- ------- ---------------
  ***MircroRNA-148a***                                                  
  OS                     0.16           0.876           0.91    0.386   −1.970--4.627
  DFS/PRS/RFS            0.24           0.806           0.25    0.820   0.591--6.947
  ***MircroRNA-148b***                                                  
  OS                     0.38           0.707           −0.64   0.556   −3.514--2.193
  DFS/PRS/RFS\*                                                         
  ***MircroRNA-152***                                                   
  OS                     0.75           0.452           0.87    0.443   −3.328--6.367
  DFS /RFS\*                                                            

Insufficient observations.

Sensitivity analyses and publication bias {#s3_5}
-----------------------------------------

Sensitivity analyses were carried out to assess the influence of each individual study by omitting individual data set, the results didn\'t alter materially, which indicated that pooled HRs were quite stable (Figure [3](#F3){ref-type="fig"}).

![Sensitivity analysis for OS of miR-148a](oncotarget-08-77999-g003){#F3}

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias. The shape of the funnel plots did not reveal any visual evidence of the asymmetry, indicating that our results were statistically robust (Table [5](#T5){ref-type="table"}, Figure [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}).

###### The results of heterogeneity test

  Comparisons              Coef.    Sth. Err.   *t*     *P*     95% CI
  ------------------------ -------- ----------- ------- ------- ----------------
  ***MircroRNA-148a***                                          
  Publication year         0.896    1.261       0.71    0.516   −2.603--4.396
  Cancer type              0.0415   0.188       0.22    0.836   −0.481--0.565
  Language                 1.021    1.422       0.72    0.512   −2.925--4.396
  Assay                    −2.957   1.863       −1.59   0.188   −8.1299--2.214
  Sample size              −1.057   1.222       −0.87   0.436   −4.449--2.335
  Quality                  0.044    0.803       0.06    0.958   −2.185--2.274
  ***MircroRNA-148b***\*   \-       \-          \-      \-      \-
  ***MircroRNA-152***\*    \-       \-          \-      \-      \-

MircroRNA-148b was dropped because of insufficient observations.

![(**A**) Begg\'s funnel plot of publication bias on the relationship between miR-148b expression and OS. (**B**) Egger\'s funnel plot of publication bias. on the relationship between miR-148b expression and OS.](oncotarget-08-77999-g004){#F4}

DISCUSSION {#s4}
==========

MiR-148/152 family members have aberrant expression in normal tissue, especially in stem cells \[[@R7], [@R46]\]. MiR-148a expression in hematopoietic stem cells (HSCs) was investigated and found that miR-148a was decreased in HSCs \[[@R47]\]. Qureshi et al. reported that the miR-148b was upregulated in osteogenesis of early osteogenic differentiation of human mesenchymal stem cells \[[@R48]\]. Manaster et al. reported that in placental tissue, miR-152 was expressed at relatively low levels compared with other healthy tissues. In addition, miR-152 as a member of miRNAs was found with aberrant expression levels in different malignant tumors \[[@R43]\]. Therefore, miR-148/152 family may serve as potential biomarkers to indicate different tumor courses and outcomes.

MiR-148/152 family members are decreased in different types of cancer, indicating that they have the potential to act as tumor-suppressors. Li et al. found miR-148b was downregulated in liver cancer stem cells (LCSCs) \[[@R49]\]. Besides, Huang et al. demonstrated that miR-152 was underexpressed in HBV-related HCC tissues compared with the adjacent noncancerous hepatic tissues. Chen et al. found that low expression of miR-148a and miR-152 correlated with increased tumor size and advanced pT stage \[[@R6]\]. Furthermore, they suggested that miR-148a and miR-152 were downregulated in cancer cell lines and cancer tissue \[[@R6]\].

To the best of our knowledge, our study is the first to critically examine available literature and identify the prognostic role of miR-148/152 family in various cancers, which was evaluated by the pooled HRs from 26 published studies. In the present study, we initially performed a systematic review and meta-analysis to comprehensively and systematically evaluate the prognostic value of the miR-148/152 family expression in cancer patients. We found that lower levels of miR-148a and 148b were signifcantly associated with shorter OS, particularly in patients with HCC and NSCLC for miR-148b. Similarly, miR-152 was significantly correlated with DFS/RFS in cancer.

Published literature has confirmed that negative correlations between miR-148/152 family expression and tumor phenotypes of NSCLC, which may be better explanations for how all three miRNAs (miR-148/152 family) can function as cancer suppressors in NSCLC \[[@R50]\]. The functional assays demonstrated that miR-148a inhibits epithelial-to-mesenchymal transition (EMT) in NSCLC cells by a metastasis promoter of directly targeting coiled-coil containing protein kinase 1 (ROCK1) \[[@R51]\]. Meanwhile, miR-148b suppresses cell migration and proliferation in NSCLC cell lines by targeting carcino-embryonic antigen (CEA) \[[@R52]\]. In blood, circulating miRNAs are stabilized by interaction with microvesicles and RNA-binding proteins so as to resist the endogenous RNase activity, and exist as cell-free forms \[[@R53]\]. The miR-148b suppresses proliferation and invasion of HCC cells by direct targeting neuropilin-1, the molecules could be detected not only in in body fluids (serum, plasma, cerebral spinal fluid and urine) but also tumor tissues, it expression was decreased in HCC \[[@R54], [@R55]\]. Evidence has been increasing that miR-152 may act as a tumor suppressor gene by regulating corresponding target genes, which are associated with migration, cell proliferation and invasion in human cancer \[[@R8]\].

MiR-148/152 family is also regulated by other pathways. Zheng et al. reported a significant inverse association between miR-148a level and lymph node metastasis in GC, and implied that the invasion and migration of GC cells was suppressed via targeting Rho-associated, ROCK1 by miR-148a \[[@R56]\]. Moreover, Song et al. noted that miR-148b may act as a tumor suppressor in colorectal cancer and GC \[[@R57]\], and indicated that the suppression of tumor growth might be fulfilled by targeting cholecystokinin-2 receptor (CCK2R) \[[@R58]\].

Although meta-analysis is robust, several limitations should be addressed as follows. Firstly, although we find no evidence of publication bias, most included papers were English, which may generate publication bias. Secondly, due to not all the included studies provide multivariate adjusted HRs, in this case, some data was extracted from survival curves. These calculated HRs with the 95%CIs might be brought several tiny errors. Thirdly, the definition in miR-148/152 family cut-off is ambiguous. Although most of them defined median as the cut-off of elevated miR-148/152 family expression, the actual values may be various between the different study populations. Therefore, the present study could not establish the exact cut-off value. Fourthly, due to the limited availability of eligible studies, stratified study hasn\'t been conducted for miR-152. Finally, the influence of adjuvant therapies on the prognosis of cancers was not evaluated in this study due to few included studies provided such data. More large-scale and well-designed studies are required to update the findings of this meta-analysis. In spite of these limitations, our work is the first meta-analysis to assess the prognostic significance of miR-148/152 family expression of patients with cancer.

In conclusion, our findings demonstrate that low miR-148a/b family expression is significantly associated with poor prognosis and may be a suitable prognostic biomarker in some cancer types, especially in HCC and NSCLC. More multicenter and well-designed studies with larger sample sizes should be conducted to confirm and update these findings.
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